. 2020 Mar 11;27(5):295–308. doi: 10.1530/ERC-19-0446
This work is licensed under a Table 1.
Clinical characteristics of included cases.
| Parameter | FTA (n = 43) | FT-UMP (n = 7) | FTC (n = 94) | HuCC (n = 24) | ||||
|---|---|---|---|---|---|---|---|---|
| Observation | No of inf. (n) | Observation | No of inf. (n) | Observation | No of inf. (n) | Observation | No of inf. (n) | |
| Mean age at diagnosis, years (min–max) | 51 (25–87) | 43 | 49 (30–75) | 7 | 54 (10–91) | 94 | 59 (29–80) | 24 |
| Female patients, n (%) | 31 (72.1) | 43 | 7 (100) | 7 | 60 (63.8) | 94 | 16 (66.7) | 24 |
| Mean tumor diameter, mm (min–max) | 32 (14–60) | 43 | 33 (15–70) | 7 | 43 (15–100) | 90 | 43 (20–80) | 24 |
| WHO 2017 subtype | 93 | 24 | ||||||
| Minimally invasive (miFTC), n (%) | – | – | 40 (43.0) | 9 (37.5)a | ||||
| Encapsulated angioinvasive (eai FTC), n (%) | – | – | 13 (14.0) | 5 (20.8)a | ||||
| Widely invasive (wiFTC), n (%) | – | – | 40 (43.0) | 10 (41.7)a | ||||
| T category | 91 | 24 | ||||||
| pT1 | – | – | 11 (12.1) | 2 (8.3) | ||||
| pT2 | – | – | 28 (30.8) | 8 (33.3) | ||||
| pT3 | – | – | 52 (57.1) | 13 (54.2) | ||||
| pT4 | – | – | 0 (0) | 1 (4.2) | ||||
| Hürthle cell, n (%) | 15 (34.9) | 43 | 4 (57.1) | 7 | 0 (0) | 94 | 24 (100) | 24 |
| Extrathyroidal growth, n (%) | – | – | 7 (7.6) | 92 | 4 (16.7) | 24 | ||
| Mean Follow-up time, months (min-max) | 70 (23–140) | 43 | 104 (9–336) | 98 (7–389) | 94 | 95 (13–328) | 24 | |
| Outcome | 43 | 7 | 94 | 24 | ||||
| AWOD, n (%) | 40 (93) | 5 (71.4) | 64 (68.1) | 15 (62.5) | ||||
| AWD, n (%) | 0 (0) | 1 (14.3) | 8 (8.5) | 0 (0.0) | ||||
| DOD, n (%) | 0 (0) | 0 (0) | 11 (11.7) | 7 (29.2) | ||||
| DOOC, n (%) | 3 (7) | 1 (14.3) | 11 (11.7) | 2 (8.3) | ||||
aSubtypes as defined for FTCs. No such subtyping is recommended for HuCCs according the 2017 WHO but are listed here for clarity.
AWD, alive with disease; AWOD, alive without disease; DOD, dead of disease; DOOC, dead of other cause; FTA, follicular thyroid adenoma; FTC, follicular thyroid carcinoma; FT-UMP, follicular tumour of uncertain malignant potential; HuCC, Hürthle cell carcinoma; No of inf., Number of informative cases.